The stock price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) has surged by 0.77 when compared to previous closing price of 1.95, but the company has seen a 1.29% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-17 that LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai’i Convention Center, Honolulu, HI. “Building on our data presented at ASH in December, we come to Tandem with an updated health economic cost model directly comparing the cost of adverse events of AUCATZYL® versus other CAR-T cell therapies, which demonstrates that the shorter duration and lower incidence of CRS and ICANS contributes to a reduction in healthcare costs,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Is It Worth Investing in Autolus Therapeutics plc ADR (NASDAQ: AUTL) Right Now?
AUTL has 36-month beta value of 2.03. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUTL is 240.31M, and currently, short sellers hold a 3.79% ratio of that float. The average trading volume of AUTL on February 21, 2025 was 1.44M shares.
AUTL’s Market Performance
AUTL’s stock has seen a 1.29% increase for the week, with a -9.03% drop in the past month and a -34.28% fall in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 5.76% for Autolus Therapeutics plc ADR The simple moving average for the last 20 days is -5.61% for AUTL stock, with a simple moving average of -43.78% for the last 200 days.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Goldman repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Goldman is $7.60 based on the research report published on November 18, 2024 of the previous year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $13. The rating they have provided for AUTL stocks is “Buy” according to the report published on November 15th, 2024.
Deutsche Bank gave a rating of “Buy” to AUTL, setting the target price at $10 in the report published on November 09th of the previous year.
AUTL Trading at -13.89% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.67% of loss for the given period.
Volatility was left at 5.76%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares sank -12.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.14% lower at present.
During the last 5 trading sessions, AUTL rose by +2.84%, which changed the moving average for the period of 200-days by -52.39% in comparison to the 20-day moving average, which settled at $2.0833. In addition, Autolus Therapeutics plc ADR saw -16.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUTL starting from Martin Pule, who proposed sale 698,741 shares at the price of $4.23 back on Sep 16 ’24. After this action, Martin Pule now owns shares of Autolus Therapeutics plc ADR, valued at $2,955,674 using the latest closing price.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -17.4 for the present operating margin
- 0.52 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -22.77. The total capital return value is set at -0.27. Equity return is now at value -82.20, with -43.81 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.7. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -2.94.
Currently, EBITDA for the company is -156.77 million with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of -7.13. The receivables turnover for the company is 11.95for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.64.
Conclusion
To put it simply, Autolus Therapeutics plc ADR (AUTL) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
